This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy MEI Pharma stock | $2.91

Own MEI Pharma stock in just a few minutes.


Fact checked

MEI Pharma, Inc is a biotechnology business based in the US. MEI Pharma shares (MEIP) are listed on the NASDAQ and all prices are listed in US Dollars. MEI Pharma employs 51 staff and has a trailing 12-month revenue of around USD$31.6 million.

How to buy shares in MEI Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for MEI Pharma. Find the stock by name or ticker symbol: MEIP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until MEI Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.91, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of MEI Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of MEI Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

MEI Pharma share price

Use our graph to track the performance of MEIP stocks over time.

MEI Pharma shares at a glance

Information last updated 2020-12-03.
Latest market close USD$2.91
52-week range USD$0.72 - USD$4.46
50-day moving average USD$2.8283
200-day moving average USD$3.141
Wall St. target price USD$9.45
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.754

Buy MEI Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy MEI Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

MEI Pharma price performance over time

Historical closes compared with the close of $2.91 from 2020-12-04

1 week (2020-11-25) 0.34%
1 month (2020-11-05) 4.30%
3 months (2020-09-04) 18.29%
6 months (2020-06-05) -21.98%
1 year (2019-12-05) 50.00%
2 years (2018-12-04) 3.93%
3 years (2017-12-05) 29.33%
5 years (2015-12-04) 88.96%

Is MEI Pharma under- or over-valued?

Valuing MEI Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MEI Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MEI Pharma's PEG ratio

MEI Pharma's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 20.6. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MEI Pharma's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

MEI Pharma financials

Revenue TTM USD$31.6 million
Gross profit TTM USD$26.2 million
Return on assets TTM -12.15%
Return on equity TTM -69.62%
Profit margin -142.81%
Book value $0.732
Market capitalisation USD$322.9 million

TTM: trailing 12 months

Shorting MEI Pharma shares

There are currently 7.4 million MEI Pharma shares held short by investors – that's known as MEI Pharma's "short interest". This figure is 4% down from 7.7 million last month.

There are a few different ways that this level of interest in shorting MEI Pharma shares can be evaluated.

MEI Pharma's "short interest ratio" (SIR)

MEI Pharma's "short interest ratio" (SIR) is the quantity of MEI Pharma shares currently shorted divided by the average quantity of MEI Pharma shares traded daily (recently around 564580.66971081). MEI Pharma's SIR currently stands at 13.14. In other words for every 100,000 MEI Pharma shares traded daily on the market, roughly 13140 shares are currently held short.

However MEI Pharma's short interest can also be evaluated against the total number of MEI Pharma shares, or, against the total number of tradable MEI Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MEI Pharma's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 MEI Pharma shares in existence, roughly 70 shares are currently held short) or 0.0663% of the tradable shares (for every 100,000 tradable MEI Pharma shares, roughly 66 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against MEI Pharma.

Find out more about how you can short MEI Pharma stock.

MEI Pharma share dividends

We're not expecting MEI Pharma to pay a dividend over the next 12 months.

Have MEI Pharma's shares ever split?

MEI Pharma's shares were split on a 1:6 basis on 19 December 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MEI Pharma shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for MEI Pharma shares which in turn could have impacted MEI Pharma's share price.

MEI Pharma share price volatility

Over the last 12 months, MEI Pharma's shares have ranged in value from as little as $0.72 up to $4.46. A popular way to gauge a stock's volatility is its "beta".

MEIP.US volatility(beta: 1.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MEI Pharma's is 1.7029. This would suggest that MEI Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

MEI Pharma overview

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site